FORMAC Pharmaceuticals initiates a phase 1 Proof-of-Concept (PoC) clinical trial for its silica-based drug delivery platform.

18 October 2011 – FORMAC Pharmaceuticals initiates a phase 1 Proof-of-Concept (PoC) clinical trial for its silica-based drug delivery platform.


FORMAC’s phase 1 clinical trial follows the successful outcome of the preclinical assessment of FORMAC’s silica-based drug delivery of a very poorly soluble compound and will assess the bio-availability enhancing effect of its proprietary platform in healthy volunteers when compared to a commercially available formulation.

“This is a major milestone for FORMAC Pharmaceuticals as it will provide insight into the clinical benefit of this new technology platform,” says Jan Rosier, CEO. “We aim to finalize this study by the end of 2011 to be in a position to propose the platform for clinical developments of BCS class 2 and 4 compounds in 2012”